The Tissue of Origin® Test is an Innovation in Molecular Diagnostics

Tissue of Origin® (TOO®) is a gene expression test that relies on genomic information to help identify the origin in cases that are metastatic and/or poorly differentiated. TOO® assesses 2,000 genes, covering 15 of the most common tumor types and 90% of all solid tumors. These tumors include thyroid, breast, non-small cell lung, pancreas, gastric, colorectal, liver, bladder, kidney, non-Hodgkin's lymphoma, melanoma, ovarian, sarcoma, testicular germ cell and prostate.

TOO® is FDA-cleared, Medicare-approved, and provides extensive analytical and clinical validation for statistically significant improvement in accuracy over other methods, including IHC. TOO® leads to a change in patient treatment 65% of the time and in challenging cancers that require a second round of IHC, TOO® increases diagnostic accuracy and confidence in site-specific treatment decisions.

Clinical Indications

Thyroid cancer, breast cancer, non-small cell lung cancer, pancreatic cancer, gastric cancer, colorectal cancer, liver cancer, bladder cancer, kidney cancer, non-hodgkin's lymphoma, melanoma, ovarian cancer, sarcoma, testicular germ cell cancer, and prostate cancer.

Clinical Utility

Tissue of Origin® is supported by extensive analytical and clinical validation data from robust, multi-centered clinical studies. In a reproducibility analysis, the Tissue of Origin® test demonstrated an average of 89% overall concordance across 3 laboratories in a cross-laboratory comparison study of 149 metastatic and poorly differentiated and undifferentiated tissue specimens. A majority of the oncologists identified the Tissue of Origin® test results as influencing the decision to make a change in therapy.

Cascade of Testing to Targeted Therapy

How the Test Works

Similarity Scores Generated

- Colorectal: 88.2
- Pancreas: 4.4
- Non-small Cell Lung: 2.3
- Breast: 2.1
- Gastric: 1.2
- Kidney: 0.6
- Hepatocellular: 0.3
- Ovarian: 0.3
- Soft Tissue Sarcoma: 0.1
- Non-Hodgkin's Lymphoma: 0.1
- Thyroid: 0.1
- Prostate: 0.1
- Melanoma: 0.1
- Bladder: 0.1
- Testicular Germ Cell: 0.0

Cancer Genetics, Inc.  www.cancergenetics.com
Identifying the Primary Tissue Type Helps Physicians Choose the Most Appropriate Treatment

With metastatic tumors or primary tumors that are undifferentiated or poorly differentiated, the Tissue of Origin® test can fill the information gap with accurate, objective, actionable information.

When to Order TOO®

- The tumor is poorly differentiated or undifferentiated.
- There is an unresolved differential diagnosis of 2 or more cancer types
- The specimen is small, constraining the diagnostic work up and limiting prognostic studies
- The patient has a history of multiple cancers
- IHC are inconclusive or conflicting after the first round
- Clinical history and histology differ on the diagnosis
- There is atypical distribution of metastases
- Oncology and Pathology differ on the diagnosis
- The diagnosis is questioned when the patient fails to respond to treatment

Patient Benefits

- Reduced need for repeated testing, examinations, imaging / biopsy procedures.
- Opportunity to enter appropriate clinical trials.
- Important information in assessing one’s familial risks for cancer.
- Knowing the primary tissue type with greater certainty helps physicians choose the most appropriate treatment regimens.

Reporting

For each tumor specimen, the Tissue of Origin® test report provides Similarity Scores (SS) that are graphically represented. SS measure the similarity of the RNA expression pattern of the specimen to the RNA expression pattern of the indicated tissue. SS range from 0 (low) to 100 (high) and sum of 100 across 15 tumor types on the panel: bladder, breast, colorectal, gastric, hepatocellular, kidney, non-small cell lung, non-Hodgkin’s lymphoma, melanoma, ovarian, pancreatic, prostate, soft tissue sarcoma, testicular germ cell and thyroid. The test provides an accurate, objective result with the ability to rule in or rule out tissues to increase the accuracy of the diagnosis. Tissue of Origin® test clinical report is interpreted and signed by a CGI staff pathologist.

Specimen Requirements

FFPE block containing at least 1 mm² of tumor tissue by area and an H&E stained slide if possible. Unstained slides of at least 5 μm thickness (10 μm thickness preferred) that contain no less than 1 mm² of tumor tissue. A study published in the peer-reviewed journal (Cancer Cytopathology) demonstrated the capability of the Tissue of Origin® test to be performed on a variety of body fluid cytology specimens preserved in FFPE. The test successfully yielded results in 89% of the specimens examined, and correctly identified the available diagnosis with a 94.1% agreement.

TAT 5-11 days

CPT Codes 81504

CGI Laboratory Licensure

CAP (Laboratory #: 7191582 AU-ID: 1434060 (NJ); 8033768 AU-ID: 1636028 (NC); 7209131(CA)), CLIA (Certificate #: 31D1038733 (NJ); 34D1009209 (NC); 05D1066073 (CA)), New Jersey (CLIS ID #: 0002299), New York State (PFI: 8192), Pennsylvania (031978), Florida (800018142), Maryland (1395), California (COS00800558) (CA)

References: